ScoreWhy is Oncopeptides AB ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 13.09% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -546.33
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 9.89%, its profits have fallen by -1.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Oncopeptides AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Oncopeptides AB
9.89%
-0.48
118.68%
OMX Stockholm 30
10.97%
0.59
18.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
135.37%
EBIT Growth (5y)
13.09%
EBIT to Interest (avg)
-546.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.91
Sales to Capital Employed (avg)
0.38
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-19.96
EV to EBIT
-5.24
EV to EBITDA
-5.24
EV to Capital Employed
-108.59
EV to Sales
27.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -216.49 MM
NET SALES(HY)
At SEK 38.78 MM has Grown at 110.53%
NET PROFIT(HY)
Higher at SEK -126.07 MM
ROCE(HY)
Highest at 0%
DEBTORS TURNOVER RATIO(HY)
Highest at 3.55 times
-5What is not working for the Company
INTEREST(9M)
At SEK 22.73 MM has Grown at inf%
CASH AND EQV(HY)
Lowest at SEK 230.17 MM
Here's what is working for Oncopeptides AB
Net Sales
At SEK 38.78 MM has Grown at 110.53%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Operating Cash Flow
Highest at SEK -216.49 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Net Profit
Higher at SEK -126.07 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Debtors Turnover Ratio
Highest at 3.55 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Oncopeptides AB
Interest
At SEK 22.73 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Cash and Eqv
Lowest at SEK 230.17 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
